Compare COST & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COST | AMGN |
|---|---|---|
| Founded | 1976 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.4B | 188.0B |
| IPO Year | 1994 | 2000 |
| Metric | COST | AMGN |
|---|---|---|
| Price | $980.78 | $346.70 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 20 |
| Target Price | ★ $1,078.32 | $348.05 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | 0.52% | ★ 2.87% |
| EPS Growth | 9.96 | ★ 88.23 |
| EPS | 9.08 | ★ 14.23 |
| Revenue | ★ $275,235,000,000.00 | $25,424,000,000.00 |
| Revenue This Year | $10.59 | $4.97 |
| Revenue Next Year | $7.66 | $2.49 |
| P/E Ratio | $109.97 | ★ $24.66 |
| Revenue Growth | 8.17 | ★ 8.83 |
| 52 Week Low | $844.06 | $265.66 |
| 52 Week High | $1,067.08 | $391.29 |
| Indicator | COST | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 44.10 |
| Support Level | $966.60 | $344.95 |
| Resistance Level | $992.14 | $353.25 |
| Average True Range (ATR) | 18.37 | 7.53 |
| MACD | -0.04 | 0.38 |
| Stochastic Oscillator | 25.19 | 52.25 |
Founded in 1983, Costco Wholesale now operates a global chain of membership-based warehouse clubs, delivering high-quality goods and services at consistently low prices. As of its most recent fiscal year, Costco operated approximately 910 warehouses, serving more than 80 million members across its three geographic segments: Costco US (approximately 73% of total revenue), Costco Canada (13%), and Costco International (14%).Costco's core value proposition—quality products at unbeatable prices—has yielded consistently strong member renewal rates (93% in the US and Canada and nearly 90% internationally). About 55% of Costco's fiscal 2025 revenue came from its grocery offerings, and another 25% from general merchandise.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.